Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition

cic.isFulltext true es
cic.isPeerReviewed true es
cic.lugarDesarrollo Instituto Multidisciplinario de Biología Celular es
cic.version info:eu-repo/semantics/publishedVersion es
dc.date.accessioned 2016-06-21T16:06:54Z
dc.date.available 2016-06-21T16:06:54Z
dc.identifier.uri https://digital.cic.gba.gob.ar/handle/11746/2280
dc.title Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition en
dc.type Artículo es
dcterms.abstract Aim of study: In the present study, we evaluated the effect of ribavirin and metformin on the sensitivity of oxaliplatin and 5‑fluorouracil (5‑FU) on colon cancer. Materials and Methods: Cell viability of two commercially available colon cancer cell lines (HT29 and HCT116) were analyzed by sulforhodamine B (SRB) assay. Results: A clinically achievable and nontoxic concentration of ribavirin and metformin showed a significant synergistic effect on oxaliplatin in HT29 and HCT116 cell lines. Ribavirin showed a synergistic effect on oxaliplatin in HT29 (R = 2.93, P < 0.001) and HCT116 (R = 1.71, P < 0.001), while only in HT29 metformin synergized with oxaliplatin by 2.66 (± 0.28, P < 0.01). In addition, both cell lines showed significant differences in response to Compound 968, inhibitor of mitochondrial glutaminase activity. Conclusion: The data suggested that these cell lines not only turn to metabolic different sustainability process after oxaliplatin treatment but that they also have different basal metabolic requirements of glutamine in vitro which can be exploits in the future for colorectal cancer (CRC) treatment and further studies are required. en
dcterms.creator.author Richard, Silvina Mariel es
dcterms.creator.author Martinez Marignac, Verónica L. es
dcterms.extent p. 336-340 es
dcterms.identifier.other DOI 10.4103/0973-1482.157317 es
dcterms.identifier.url Documento completo es
dcterms.isPartOf.issue vol. 11, nº 2 es
dcterms.isPartOf.series Journal of Cancer Research and Therapeutics es
dcterms.issued 2015-06
dcterms.language Inglés es
dcterms.license Attribution 4.0 International (BY 4.0) es
dcterms.publisher Association of Radiation Oncologists of India es
dcterms.subject Neoplasias Colorrectales es
dcterms.subject Metformina es
dcterms.subject oxaliplatino es
dcterms.subject Ribavirina es
dcterms.subject.materia Biología Celular, Microbiología es
Archivos
Paquete original
Mostrando 1 - 1 de 1
Imagen en miniatura
Nombre:
Sensitization_to_oxaliplatin_bitstream_5578.pdf-PDFA.pdf
Tamaño:
587.31 KB
Formato:
Adobe Portable Document Format
Descripción:
Documento completo